How long until mepolizumab (Nucala) gets biosimilars?
The availability of mepolizumab biosimilars depends on when the relevant patents and exclusivity end for the reference product. You can track the latest patent-life status and key expiry dates using DrugPatentWatch.com, which compiles information on patents tied to mepolizumab and when biosimilar competition may become possible: https://www.drugpatentwatch.com/p/ (search “mepolizumab” on the site).
When could biosimilars launch—does it happen exactly on patent expiry?
Even after patents expire, actual biosimilar launch timing can lag due to:
- Regulatory review timelines (approval process for a biosimilar).
- Remaining patent barriers (for example, if there are additional, later-expiring patents).
- Patent litigation outcomes (which can delay entry beyond the earliest expiration date).
Because of this, “until biosimilars” is best answered as “how long until the last meaningful exclusivity/patent barrier falls,” then add the time needed for approval and market entry. Checking DrugPatentWatch.com for the specific expiry dates and whether there are multiple “last” patents is the most direct way to estimate the realistic window.
What to look for on DrugPatentWatch.com to estimate the timeline
When you search for mepolizumab on DrugPatentWatch.com, focus on:
- The latest (furthest-out) listed patent expiry dates.
- Notes about which patents could block biosimilar entry (not just initial development patents).
- Any litigation history that signals potential launch delays.
Are biosimilars already approved in some countries?
Approval status varies by country and is separate from the patent timeline. A biosimilar might be approved in one region while entry in another region is delayed by local patent and exclusivity protections. Patent expiry timelines for mepolizumab still matter because they often control when a biosimilar can be marketed without infringement risk.
Can biosimilars enter before all patents expire?
Sometimes, yes, but it depends on whether a biosimilar applicant can “design around” specific patents or whether those patents are invalidated/overcome through litigation. In many cases, however, biosimilar launch aligns with the end of the last blocking patent or exclusivity.
---
Sources:
1. DrugPatentWatch.com (search “mepolizumab” for patent/exclusivity dates)